ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ADCT vs RNAC // OPERATING MARGIN

ADC Therapeutics SA (NYSE) VS. Cartesian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADCT 4 — RNAC 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADCT VS. RNAC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ADCT RNAC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 92.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 14.90% -65.00% +79.90 ADCT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 ADCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.3 40.2 +14.10 ADCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $196.6M $191.8M $4.8M ADCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ADCT REV RNAC REV ADCT GROSS % RNAC GROSS % ADCT FCF RNAC FCF
FY 2025 $81.4M $400.0K 92.9% — -$141.4M -$79.4M
FY 2024 $70.8M $38.3M 91.6% — -$124.7M -$32.8M
FY 2023 $69.1M $26.0M — — -$118.7M -$51.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADCT // BETA —
RNAC // BETA —